Atara Biotherapeutics (NASDAQ:ATRA) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a neutral rating on shares of Atara Biotherapeutics in a report on Wednesday, May 22nd.

Atara Biotherapeutics Stock Performance

Shares of NASDAQ ATRA opened at $7.30 on Wednesday. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $63.38. The firm has a market cap of $35.16 million, a price-to-earnings ratio of -0.14 and a beta of 0.54. The stock’s 50-day simple moving average is $14.40 and its 200-day simple moving average is $16.25.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($5.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.25) by $3.50. Atara Biotherapeutics had a negative return on equity of 783.31% and a negative net margin of 671.70%. The company had revenue of $27.36 million for the quarter, compared to the consensus estimate of $27.00 million. As a group, research analysts predict that Atara Biotherapeutics will post -15.75 EPS for the current year.

Insider Transactions at Atara Biotherapeutics

In related news, EVP Anhco Nguyen sold 1,715 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $26,582.50. Following the transaction, the executive vice president now directly owns 35,939 shares in the company, valued at $557,054.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Pascal Touchon sold 3,260 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $50,530.00. Following the completion of the transaction, the chief executive officer now owns 73,165 shares in the company, valued at approximately $1,134,057.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Anhco Nguyen sold 1,715 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $15.50, for a total value of $26,582.50. Following the completion of the sale, the executive vice president now directly owns 35,939 shares in the company, valued at $557,054.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,120 shares of company stock worth $94,860. 3.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Atara Biotherapeutics

Several institutional investors have recently modified their holdings of ATRA. Delap Wealth Advisory LLC bought a new position in Atara Biotherapeutics in the 1st quarter worth about $29,000. Vontobel Holding Ltd. bought a new position in shares of Atara Biotherapeutics in the fourth quarter worth $41,000. Harbor Capital Advisors Inc. increased its holdings in shares of Atara Biotherapeutics by 368.0% during the fourth quarter. Harbor Capital Advisors Inc. now owns 208,827 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 164,206 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Atara Biotherapeutics by 29.3% during the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares in the last quarter. Finally, Josh Arnold Investment Consultant LLC lifted its holdings in Atara Biotherapeutics by 17.6% in the third quarter. Josh Arnold Investment Consultant LLC now owns 200,000 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 30,000 shares during the period. Institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.